Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2
Authors
Keywords
2019 novel corona virus, SARS-CoV-2, Spike protein, 2019-nCoV,receptor binding domain, RBD, S1 domain, ACE2
Journal
JOURNAL OF MOLECULAR GRAPHICS & MODELLING
Volume 101, Issue -, Pages 107716
Publisher
Elsevier BV
Online
2020-08-21
DOI
10.1016/j.jmgm.2020.107716
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS
- (2020) Yushun Wan et al. JOURNAL OF VIROLOGY
- Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2
- (2020) Renhong Yan et al. SCIENCE
- Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
- (2020) Wanbo Tai et al. Cellular & Molecular Immunology
- Hispidin and Lepidine E: two Natural Compounds and Folic acid as Potential Inhibitors of 2019-novel coronavirus Main Protease (2019-nCoVMpro), molecular docking and SAR study
- (2020) Talia Serseg et al. Current Computer-Aided Drug Design
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
- (2020) Philippe Gautret et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain)
- (2020) Phulen Sarma et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light
- (2020) Izabela Ragan et al. PLoS One
- Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light‐based photochemical treatment
- (2020) Shawn D. Keil et al. VOX SANGUINIS
- Coronavirus Disease 2019 (COVID‐19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
- (2020) Junyi Guo et al. Journal of the American Heart Association
- Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
- (2020) Yadi Zhou et al. Cell Discovery
- No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection
- (2020) J.M. Molina et al. MEDECINE ET MALADIES INFECTIEUSES
- Liquid biopsy with cell free DNA: new horizons for prostate cancer
- (2020) Giovanni Ponti et al. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
- DrugBank 5.0: a major update to the DrugBank database for 2018
- (2017) David S Wishart et al. NUCLEIC ACIDS RESEARCH
- Acarbose Monotherapy and Type 2 Diabetes Prevention in Eastern and Western Prediabetes: An Ethnicity-specific Meta-analysis
- (2015) Ruijie Hu et al. CLINICAL THERAPEUTICS
- Bat-to-human: spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyond
- (2015) Guangwen Lu et al. TRENDS IN MICROBIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search